Thus, we chose DLBCL models with high expression of MCT1 but negative for MCT4 and considered MDA-MB-231—a breast cancer model, negative for MCT1 but positive for MCT4—a suitable insensitive control. Here, SLC16A3 is linked to breast carcinoma.